Revenue Recognition - Additional Information (Detail) (USD $)	3 Months Ended			12 Months Ended	1 Months Ended	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013 Pfizer Incorporation Nonsoftware License Arrangement	Dec. 31, 2012 Pfizer Incorporation Nonsoftware License Arrangement	Jan. 31, 2013 Pfizer Incorporation Nonsoftware License Arrangement Up-front Payment Arrangement	Mar. 31, 2013 Orencia Royalties from Bristol	Mar. 31, 2012 Orencia Royalties from Bristol	Jun. 30, 2013 Deferred Revenue Pfizer Incorporation Nonsoftware License Arrangement
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Royalty revenue	$ 4,521,724	$ 3,481,860				$ 3,846,000	$ 3,081,000
Percentage of royalty revenue, remittance to the University of Michigan	15.00%
Cost of royalty and other revenue	576,857	462,088				577,000	462,000
Payment received under license agreement					5,000,000
Total future milestone receivable			65,000,000
License agreement, revenue recognized			55,000	4,876,000				69,000
Revenue from sponsored research and development projects	$ 621,000	$ 401,000